BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20581016)

  • 1. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy.
    de la Torre I; Moura RA; Leandro MJ; Edwards J; Cambridge G
    Ann Rheum Dis; 2010 Dec; 69(12):2181-8. PubMed ID: 20581016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
    Cambridge G; Perry HC; Nogueira L; Serre G; Parsons HM; De La Torre I; Dickson MC; Leandro MJ; Edwards JC
    J Autoimmun; 2014 May; 50():67-76. PubMed ID: 24365380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
    Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
    Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
    Becerra E; Scully MA; Leandro MJ; Heelas EO; Westwood JP; De La Torre I; Cambridge G
    Clin Exp Immunol; 2015 Mar; 179(3):414-25. PubMed ID: 25339550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
    Carter LM; Isenberg DA; Ehrenstein MR
    Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.
    Becerra E; De La Torre I; Leandro MJ; Cambridge G
    Clin Exp Immunol; 2017 Dec; 190(3):372-383. PubMed ID: 28800164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
    Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
    Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
    Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
    Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
    Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis.
    Gremese E; Tolusso B; Fedele AL; Canestri S; Alivernini S; Ferraccioli G
    J Rheumatol; 2012 Dec; 39(12):2276-85. PubMed ID: 22984268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.
    Moura RA; Quaresma C; Vieira AR; Gonçalves MJ; Polido-Pereira J; Romão VC; Martins N; Canhão H; Fonseca JE
    PLoS One; 2017; 12(9):e0182927. PubMed ID: 28886017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
    Roll P; Dörner T; Tony HP
    Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics.
    De La Torre I; Leandro MJ; Valor L; Becerra E; Edwards JC; Cambridge G
    Rheumatology (Oxford); 2012 May; 51(5):833-40. PubMed ID: 22253030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
    Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
    J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
    Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
    J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
    Leandro MJ; Cooper N; Cambridge G; Ehrenstein MR; Edwards JC
    Rheumatology (Oxford); 2007 Jan; 46(1):29-36. PubMed ID: 16735454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.